Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Short Interest Update

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) (TSE:CPH) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totalling 130,300 shares, a decline of 8.8% from the November 30th total of 142,800 shares. Based on an average daily volume of 51,200 shares, the days-to-cover ratio is currently 2.5 days.

Cipher Pharmaceuticals Stock Performance

Shares of CPHRF traded down $0.01 during mid-day trading on Monday, reaching $9.94. The stock had a trading volume of 6,288 shares, compared to its average volume of 22,576. Cipher Pharmaceuticals has a 12 month low of $4.14 and a 12 month high of $14.60. The business has a fifty day moving average of $10.57 and a 200 day moving average of $9.95.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.